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Abstract
Background: We evaluated the quality of patient information leaflets for Trans-Rectal Ultrasound guided prostate
biopsies (TRUS-Bx) in North Thames region. TRUS-Bx information leaflets were requested from 24 hospitals in the
region. All hospitals were contacted by telephone, and non-responders were followed-up by postal survey. Leaflets
received were evaluated for a clear description of the procedure, directions to TRUS-Bx location, a clear description
of the procedure, contact for queries/concerns, information about preparation prior to procedure, information
about regular medication, information on how to obtain results, instructions for follow-up arrangements, analgesia
used and risk of morbidity/mortality. Additionally, the leaflets were evaluated for diagrams to clarify the procedure
and the anatomy, and sources of additional information, such as reference to published articles or prostate cancer
patient support groups/internet websites.
Findings: In summary, a total of 17 leaflets (77%) were received. Of these, the majority (94%) had a clear
description of the procedure, contact for queries/concerns (82%), information about preparation prior to TRUS-Bx
(71%). Directions to TRUS-Bx location (29%), and analgesia used (35%), was very poorly described, and information
on obtaining results and follow-up arrangements were described in only 12 (71%) leaflets. Complications such as
risks of infection, haematuria, haematospermia and rectal bleeding, were generally explained (71%-76% of leaflets),
urinary retention was mentioned in only 5 (29%) leaflets and mortality in only 1 case. Descriptive diagrams of the
procedure and prostate anatomy were very rarely used, and sources of additional information were limited to 1
published article and reference to 1 prostate cancer support group.
Conclusions: This study demonstrates that there is large variation in the information supplied in TRUS-Bx patient
information leaflets in the North Thames region, with some leaflets lacking vital information. It is proposed that a
standard patient information leaflet incorporating all the factors in the checklist should be designed, with the
incorporation of a new BAUS procedure specific consent form for TRUS-Bx.
Findings
Introduction
A recent UK white paper suggests that all patients
should have improved access to high quality informa-
tion, health professionals should communicate more
effectively with patients, and there should be a nation-
ally coordinated process to produce and deliver informa-
tion [1]. Patient information leaflets are a good example
of how this can be achieved, for several important rea-
sons [2]. Importantly, they allow improved
communication between doctors and patients, which is
especially useful in the process of informed consent, as
well as reducing patient anxiety [3].
Trans-Rectal Ultrasound guided prostate biopsy
(TRUS-Bx) is a common outpatient procedure that is
undertaken when a diagnosis of prostate cancer is sus-
pected. Although it is relatively quick to perform and is
done under local anaesthetic, it is nevertheless an inva-
sive procedure, that may cause significant anxiety to
patients. In addition, it may potentially result in morbid-
ity and mortality. Complications include septicaemia,
haematuria, haematospermia, rectal bleeding and urinary
retention. Despite national advice that the patient
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should be provided with comprehensive information
about TRUS-Bx procedure [4,5], the short contact time
between a patient and the doctor in many urology diag-
nostic units may be insufficient to fully inform and pre-
pare the patient adequately for the procedure. This is
especially the case with the introduction of the one-stop
clinic, for suspected prostate cancer via the two-week-
wait referral system, where patients are seen, assessed
and then undergo TRUS-Bx within a matter of minutes.
Interestingly, even though several written information
sheets for informed consent exist for urological proce-
dures [6] TRUS-Bx is not included. Furthermore, there
is no national standardised patient information sheet
that exists, contrary to suggestions in the recent UK
white paper, for diagnostic procedures such as TRUS-
Bx.
Hence, with the understanding that a lack of appropri-
ate health information can have potentially serious or
even fatal consequences [7], we evaluated the quality of
patient information leaflets for TRUS-Bx, in the North
Thames Deanery.
Materials and Methods
TRUS-Bx information leaflets were requested from the
24 hospitals in the North Thames region that perform
this procedure. All hospitals were initially contacted by
telephone, and non-responders were then followed-up
by postal survey. Leaflets received were then evaluated
against a checklist of 17 items (Table 1). In the absence
of an established checklist for this purpose, several
sources were used to derive this checklist. This included
The British Society of Gastroenterology [8], guidelines
for items that should be included in any information
sheet, originally developed for patients undergoing
upper gastrointestinal endoscopic procedures, a similar
study in the Urology literature investigating flexible
cystoscopy information leaflets [9] as well as the Pros-
tate Cancer Risk Management Programme (PCRMP)
guidance on undertaking a TRUS-Bx of the prostate [4]
and the NICE guidelines for prostate cancer [5]. Addi-
tionally, the leaflets were evaluated for diagrams to clar-
ify the procedure and the anatomy, and sources of
additional information, such as reference to published
articles or prostate cancer patient support groups/inter-
net websites.
Results
The results are summarized in Table 1. In summary, a
total of 17 leaflets (77%) were received. Of these, the
majority (94%) had a clear description of the proce-
dure, contact for queries/concerns (82%), information
about preparation prior to TRUS-Bx (71%). Directions
to TRUS-Bx location (29%), and analgesia used (35%),
was very poorly described, and information on
obtaining results and follow-up arrangements were
described in only 12 (71%) leaflets. Complications
such as risks of infection, haematuria, haematosper-
mia and rectal bleeding, were generally explained
(71%-76% of leaflets), urinary retention was men-
tioned in only 5 (29%) leaflets and mortality in only 1
case. Descriptive diagrams of the procedure and pros-
tate anatomy were very rarely used, and sources of
additional information were limited to 1 published
article and reference to 1 prostate cancer support
group. The majority of leaflets were produced
between 2003 and 2006 (n = 15). The date of produc-
tion of the remaining 2, were not listed.
Discussion
Summary of findings
The current study demonstrates that there is large varia-
tion in the information supplied in these in the North
Thames region, with some leaflets lacking vital informa-
tion. This has the potential risk of causing uncertainty
and misunderstanding for patients undergoing such a
common outpatient procedure.
Strengths and Weaknesses
One of the concerning findings from this survey is that
the complication of urinary retention and death follow-
ing TRUS-Bx of prostate was rarely described. PCRMP
guidance clearly states that the patient should be pro-
vided with comprehensive information about the proce-
dure, including estimates of the risks of potential
complications and post-procedure events - this includes
Table 1 Summary of checklist and results from the audit.
Checklist Item (n) %
Directions to the location of TRUS-Bx 5 29%
A clear description of the procedure 16 94%
A contact number for queries or concerns before or after
the procedure
14 82%
Information about preparation prior to procedure 12 71%
Information about regular medication 12 71%
Information on how to obtain the result of the TRUS-Bx 11 65%
Instructions for follow-up arrangements 10 59%
Analgesia mentioned? 6 35%
Risk of infection 12 71%
Risk of haematuria 13 76%
Risk of haemospermia 12 71%
Risk of rectal bleeding 13 76%
Risk of retention of urine 5 29%
Mortality 1 6%
Diagrams to clarify the procedure 3 18%
Diagrams to clarify the anatomy 3 18%
Sources of additional information 2 12%
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retention of urine and death [4]. Other complications
were explained, but not in all of the leaflets. This sug-
gests that important complications are being omitted
which is contrary to national advice from PCRMP. An
alternative explanation is that patients are being coun-
selled thoroughly on the day of biopsy and are given
information on discharge following the biopsy, as per
PCRMP advice [4], although this cannot be inferred
directly from this survey.
Information regarding preparation prior to procedure
included requirements for antibiotic prophylaxis, which
were variable, and the use of enemas, even though there
is no requirement for patients to be given an enema
before undergoing the procedure, according to PCRMP
guidance [4].
Several leaflets provided no information about fasting
in preparation for the procedure. This lack of informa-
tion may have resulted in unnecessary discomfort to
those patients who fasted, especially patients with dia-
betes. In addition, information and advice regarding reg-
ular medication was missing in almost a third of cases,
and one leaflet stated “Do not stop taking your medica-
tion until advised”. Clearly, this may have important
implications regarding complications as anticoagulant
therapy in the form of warfarin and anti-platelet agent
clopidogrel which should be stopped before undertaking
TRUS-BX [4,5]. According to our survey, although sev-
eral leaflets stated that warfarin and clopidogrel should
be stopped prior to TRUS-Bx, only one leaflet stated
that bleeding was more likely if patients were taking
warfarin. One leaflet stated “please inform us if you
have a latex allergy”, but this may reflect an increased
prevalence of this problem in that hospitals catchment
area.
Furthermore, only two leaflets gave advice on continu-
ing the usual dose of any regular medication, apart from
anticoagulants. Again, this lack of information is worry-
ing, as it is possible that some patients may omit their
drugs, such as those for diabetes, with dangerous conse-
quences. One method of overcoming these problems is
to involve patients in the development of patient infor-
mation leaflets, in close conjunction with clinicians [2].
We were surprised to find that the type of analgesia to
be used was only mentioned in a third of leaflets, espe-
cially as there is strong recent evidence suggest that it
TRUS-Bx may be a painful procedure and that patient
tolerance and comfort can be improved by analgesia
[10].
Of all the leaflets, illustrations or diagrams were only
used in six and only one used photographs. All illustra-
tions, except one, was labelled, in accordance with the
NHS Toolkit, which has been introduced by the Depart-
ment of Health for help in producing patient
information and endorses the use of illustrations and
diagrams advising that they should be clearly labelled
and not overwritten [11].
Implications for practice and research
Although a significant number of leaflets had informa-
tion regarding contact details (Urology department or
Uro-Oncology Nurse Specialists numbers) only one leaf-
let made it clear which source of information was used
to compile the publication, and only one leaflet provided
any details of additional sources of support and informa-
tion (a support association). These items are questions
in the DISCERN tool [12,13], which was developed to
assess a broad range of aspects of the quality of infor-
mation. Although not used in this survey, as it specifi-
cally applies to treatment choices, DISCERN scores of
relevant questions from the leaflets studied would have
been very low, indicating low or moderate quality infor-
mation. Furthermore, the PCRMP was not referenced in
any of the leaflets, possibly as the majority of leaflets
were old and had not been updated appropriately [13].
The implications, based on the information from this
survey, are that a national standardised patient informa-
tion sheet for TRUS-BX should be produced and a
detailed audit, with laid-out criteria/standards, should be
undertaken after a new leaflet has been designed.
In summary, results from this survey suggest that
there is large variation in the information supplied in
TRUS-Bx patient information leaflets in the North
Thames region, with some leaflets lacking vital informa-
tion. It is proposed that a standard patient information
leaflet incorporating all the factors in the checklist
should be designed, and in addition, we believe that
templates from the NHS toolkit [11] as well as incor-
poration of a new BAUS procedure specific consent
form would help standardise the quality and presenta-
tion of patient information for TRUS-Bx.
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